Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antimicrobials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Antimicrobials. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-004880-29 Sponsor Protocol Number: HUB-INF-RADICAP Start Date*: 2019-10-02
    Sponsor Name:Dr. Jordi Carratalà Fernández (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge
    Full Title: Phase IV randomized, controlled, open and multicentre clinical trial with two parallel groups, to assess the impact of integral molecular tests in the antimicrobial use in community-acquired pneumo...
    Medical condition: Community-acquired pneumonia (CAP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10035664 Pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001376-38 Sponsor Protocol Number: LOCKIA Start Date*: 2019-08-13
    Sponsor Name:María Dolores Sousa Regueiro
    Full Title: Antimicrobials Local Administration for Intraabdominal Abscesses Treatment: Controlled, Randomized, Open, Parallel Groups, Clinical Trial
    Medical condition: Intra-abdominal abscesses
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001769-35 Sponsor Protocol Number: OYS042020. Start Date*: Information not available in EudraCT
    Sponsor Name:Oulu University Hopsital
    Full Title: Preventing urinary tract infections in infants and young children with probiotic E. coli Nissle: FinNiss- trial
    Medical condition: Urinary tract infection
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004736-51 Sponsor Protocol Number: nov 2005 Start Date*: 2006-09-26
    Sponsor Name:Prof V Lund
    Full Title: Double-blind randomized placebo-controlled multinational, multicentre-trial on prolonged macrolide treatment in patients with moderate/severe chronic rhinosinusitis
    Medical condition: chronic rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001728-30 Sponsor Protocol Number: MPEX-204 Start Date*: 2008-08-26
    Sponsor Name:Mpex Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP- 376 Solution for Inhalation Given for 2...
    Medical condition: Pseudomonas aeruginosa infection in patients suffering from stable Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    9.1 10021860 Infection pseudomonas aeruginosa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-001062-14 Sponsor Protocol Number: MEC 04/265 Start Date*: 2006-02-23
    Sponsor Name:prof W.J. Fokkens, academic medical center
    Full Title: MACS Macrolides in chronic rhinosinusitis Double-blind, randomized, placebo-controlled, multinational, multicenter-trial on prolonged macrolide treatment in patients with moderate/ severe chronic...
    Medical condition: Chronic rhinosinusitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002011-33 Sponsor Protocol Number: PROGRESS Start Date*: 2017-08-28
    Sponsor Name:Hellenic Institute for the Study of Sepsis
    Full Title: A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS THE ROLE OF PROCALCITONIN-GUIDED ANTIMICROBIAL THERAPY TO REDUCE LONG-TERM INFECTIONS SEQUELAE
    Medical condition: USE OF PROCALCITONIN IN EARLY STOP OF ANTIBIOTICS TO AVOID LONG-TERM CONSEQUENCES
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022150-16 Sponsor Protocol Number: Moxifloxacin Sepsis PEG Start Date*: 2011-01-27
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.klinische Pharmakologie
    Full Title: Determination of Moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients including a pilot phase
    Medical condition: To evaluate feasibility of Moxifloxacin determination in septic patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001505-90 Sponsor Protocol Number: 18CH049 Start Date*: 2018-10-01
    Sponsor Name:CHU de Saint Etienne
    Full Title: Decolonization of patients carrying S. aureus before cardiac surgery: study of the risk factors associated with failure
    Medical condition: Decolonization of S. aureus nasal carriers before cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10075981 Staphylococcus aureus infection LLT
    20.0 100000004865 10048935 Open heart surgery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001124-19 Sponsor Protocol Number: 04-24 Start Date*: 2013-09-25
    Sponsor Name:Onconova Therapeutics, Inc.
    Full Title: Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Bl...
    Medical condition: Myelodysplastic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) SE (Completed) DK (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000599-18 Sponsor Protocol Number: P903-09 Start Date*: 2008-03-25
    Sponsor Name:Cerexa, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline versus Ceftriaxone in the Treatment of Adult Subjects with Community-Acquired ...
    Medical condition: Adult Subjects with Community-Acquired Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) DE (Completed) HU (Completed) AT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2013-002202-31 Sponsor Protocol Number: POL7080-002 Start Date*: 2013-09-11
    Sponsor Name:Polyphor Ltd.
    Full Title: A phase II, open-label, multi-center study to assess the tolerance, safety, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of POL7080 in the treatment of patients with acute exacerbation of...
    Medical condition: Acute exacerbation of non-cystic fibrosis bronchiectasis due to Pseudomonas aeruginosa infection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006096-37 Sponsor Protocol Number: BAY 12-8039/11980 Start Date*: 2008-05-09
    Sponsor Name:Bayer HealthCare AG, Leverkusen, Germany
    Full Title: A prospective, multinational, multicenter, randomized, double-blind, double-dummy, controlled study comparing the efficacy and safety of moxifloxacin to that of amoxicillin-clavulanic acid for the ...
    Medical condition: acute exacerbation of chronic bronchitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000743 Acute exacerbation of chronic bronchitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) IE (Completed) BE (Completed) DE (Completed) ES (Completed) PT (Completed) GR (Completed) LT (Completed) LV (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-005805-25 Sponsor Protocol Number: M19-771 Start Date*: 2021-11-10
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Subjects with Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation.
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002110-32 Sponsor Protocol Number: 10-0065 Start Date*: 2018-06-13
    Sponsor Name:Regents of the University of Michigan
    Full Title: DMID Protocol Number: 10-0065 OVERCOME Trial: Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli
    Medical condition: Blood stream Infection (BSI) and/or pneumonia due to extensively drug-resistant Gram-negative bacilli (XDR-GNB) including XDR-AB, CRE and XDR-PA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10004031 Bacterial infection due to other gram-negative organisms LLT
    20.1 10021881 - Infections and infestations 10035701 Pneumonia gram-negative bacterial NOS LLT
    20.1 10021881 - Infections and infestations 10064977 Acinetobacter bacteremia LLT
    20.0 10021881 - Infections and infestations 10051190 Pneumonia Pseudomonas aeruginosa LLT
    20.0 10021881 - Infections and infestations 10035679 Pneumonia due to Escherichia coli (E. Coli) LLT
    20.0 10021881 - Infections and infestations 10054280 Escherichia coli bacteraemia LLT
    20.0 10021881 - Infections and infestations 10021860 Infection Pseudomonas aeruginosa LLT
    20.1 10021881 - Infections and infestations 10023456 Klebsiella pneumonia LLT
    20.0 10021881 - Infections and infestations 10058883 Klebsiella bacteremia LLT
    20.0 10021881 - Infections and infestations 10054218 Enterobacter pneumonia PT
    20.1 10021881 - Infections and infestations 10058884 Enterobacter bacteremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) GR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000598-41 Sponsor Protocol Number: P903-08 A4 Start Date*: 2007-11-22
    Sponsor Name:Cerexa, Inc.
    Full Title: "A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline versus Ceftriaxone, with Adjunctive Clarithromycin, in the Treatment of Adult...
    Medical condition: Adults Subjects with Community-Acquired Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) AT (Completed) LT (Completed) EE (Completed) SK (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000775-32 Sponsor Protocol Number: AB.OH.2018 Start Date*: 2018-06-05
    Sponsor Name:Vall d'Hebron Institut de Recerca
    Full Title: Phase IV, randomized, open, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in febrile neutropenic Oncohematological Paediatric patients.
    Medical condition: Febrile neutrophenia in oncohematological pediatric patients.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005283-47 Sponsor Protocol Number: P903-07 Start Date*: 2006-12-29
    Sponsor Name:Cerexa, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin plus Aztreonam in Adult Subjects with Complicated Skin and ...
    Medical condition: Complicated Skin and Skin Structure Infections (cSSSI)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052891 Skin bacterial infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) DE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2006-005332-25 Sponsor Protocol Number: P903-06 Start Date*: 2007-03-16
    Sponsor Name:Cerexa, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin plus Aztreonam in Adult Subjects with Complicated Skin and ...
    Medical condition: Complicated Skin and Skin Structure Infections (cSSSI)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052891 Skin bacterial infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002366-40 Sponsor Protocol Number: 13.0095 Start Date*: 2013-07-19
    Sponsor Name:St George’s, University of London
    Full Title: Neonatal and Paediatric Pharmacokinetics of Antimicrobials study
    Medical condition: The study is not restricted to any specific condition. The study population will include children (aged under 16 years) admitted to hospital and routinely prescribed one of the study penicillins ac...
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:56:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA